Compare BioNTech SE - ADR (BNTX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Vale SA — how do they compare? BioNTech SE - ADR trades at $90.53 (market cap $23.31B), while Vale SA trades at $14.35 (market cap $62.26B). The key difference: Vale SA is far larger — about 2.7× BioNTech SE - ADR's market cap, and Vale SA pays a 8.12% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | VALE | |
|---|---|---|
Market Cap | $23.31B | $62.26B |
Sector | Health | Basic Materials |
52-Week High | $119.34 | $17.82 |
52-Week Low | $83.89 | $9.71 |
Enterprise Value | $6.60B | $78.50B |
Dividend Yield | — | 8.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
VALE trades at $14.71, showing minimal daily movement with a slight decline of 0.07%. The stock faces technical bearish signals from moving averages while fundamentals reveal mixed performance with declining net income margins from 42.85% in 2022 to 5.11% in 2026, despite recent revenue stabilization. Recent earnings misses in Q4 2025 and Q1-Q2 2026 highlight operational challenges, though the company maintains strong cash flow generation of $8.8 billion from operations in 2025.
VALE presents a cautious investment case with analyst consensus leaning neutral (51.35% hold) despite a $16.79 price target suggesting 14% upside. Key opportunities include copper segment growth and disciplined capital returns, while risks involve rising operational costs, earnings volatility, and governance concerns highlighted by recent board disputes. The stock's valuation at 29.42 P/E appears stretched given profitability declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
